Purdue Pharma LP agreed to plead guilty to criminal charges over the handling of the company’s addictive prescription opioid OxyContin, in a deal with U.S. prosecutors that effectively sidestepped paying billions of dollars in penalties and stopped short of criminally charging its executives or wealthy Sackler family owners.
If you are not happy with the results below please do another search
50 search results for:
Novartis is seeking to repurpose the company’s investigational oral spinal muscular atrophy (SMA) medicine branaplam to treat Huntington’s disease, as the Swiss drugmaker plans a clinical trial after winning U.S. orphan drug designation.
GlaxoSmithKline will move the company’s experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing after experiencing encouraging mid-stage trial results.
New York, New Jersey and Connecticut urged their residents to not travel between the three states as the U.S. Northeast sees a rise in Covid-19 cases, while California said major theme parks including Disneyland would not be opening anytime soon.
Shares of Cara Therapeutics were up in trading after the company struck a licensing agreement worth up to $290 million with Switzerland’s Vifor Pharma for the commercialization of a treatment for severe itching associated with chronic kidney disease.
Nearly 300,000 more people have died in the United States in 2020 during the coronavirus pandemic than expected based on historical trends, with about two-thirds of the deaths due to Covid-19 illnesses, according to a report.
Aptinyx Jumps Following Positive Phase II PTSD Study Results Published: Oct. 20, 2020 By Alex Keown BioSpace Shares of Aptinyx skyrocketed more than 75% after the company reported its mid-stage experimental treatment for post-traumatic stress disorder demonstrated clinically meaningful and statistically significant results that will set up a pivotal study next year. This morning, […]
Merck reported results from two more Phase III trials of the company’s 15-valent pneumococcal conjugate vaccine V114, with plans to apply for approval to regulatory agencies before the end of 2020, beginning with the U.S. Food and Drug Administration.
The UK government’s Covid-19 Vaccine Taskforce and the contract research company Open Orphan announced a $13 million (£10 million) plan to test investigational vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes Covid-19.
The U.S. health regulator’s criteria for allowing emergency use of a Covid-19 vaccine and plans to monitor its safety after a regulatory go-ahead are among the topics to be discussed at a closely watched meeting.